MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why NVAX Stock advanced +1.45% Today — RQD Quant Desk Flash
$10.47 +1.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.48
Novavax Inc. (NVAX) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $1.73B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.48 (+0.07%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-0.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NVAX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY NVAX SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+14/20 pts (25% of score)
FRED Regime × Technicals: 59% of 52W Range • RSI-14 at 44.9 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)
Capital intensity & 40.3% operating margin leave 13 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$12.75-11.7% Next Q
64
Q2 (-2Q)Grade C$11.26-13.9% Next Q
61
Q3 (-1Q)Grade C$9.70+7.9% Next Q
59
CurrentGrade D+$10.47-0.4% Hist 90D α
56
Trajectory: C+ (64) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the NVAX Bull Thesis Could Fail
Even with a 56/100 (D+) score, NVAX faces multiple-compression risk if 3.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (+0.24% YoY Shares) — any gross margin slip below 91.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.46) or 200D SMA ($9.29) invalidates the momentum regime and cuts Target Base ($10.38) toward Bear Floor ($8.10).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NVAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NVAX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NVAX Stock advanced +1.45% Today — RQD Quant Desk Flash
Novavax Inc. (NVAX) advanced +1.45% to $10.47, trading at 59% of its 52-week range ($6.2 – $13.39). Stretched risk/reward at 4x P/E (85% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 59% of its 52-week range ($6.2 – $13.39) with RSI-14 at 44.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $10.47 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 93.5% gross margin and $0 annual free cash flow.
Live NVAX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVAX)
- ✓Walkthrough of NVAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NVAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.03%▲ ASCENDING CHANNEL
2026-10-30O $10.27H $10.65L $9.92C $10.47VOL 4.06M
RES: $14.26SUP: $9.03SMA50: $10.46SMA200: $9.29
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NVAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-15.0%/yr Implied 5Y Growth
vs. +64.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NVAX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NVAX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NVAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVAX)
Health Care Rank #261 of 1016
⚔️ MAZE vs NVAX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NVAX vs. MAZE, REPL, IMCR, COAG)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Novavax Inc. (NVAX) ranks #261 by composite RQD confidence (56/100, grade D+) and #284 by equity capitalization ($1.73B). Within this direct 5-issuer industry benchmark cohort, NVAX leads on earnings valuation at 3.9x trailing P/E, while NVAX leads on capital efficiency and profitability with 85.0% ROIC and 93.5% gross margin. COAG currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with NVAX at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NVAX
ACTIVE
Novavax Inc. | D+ | 56/100 | 3.9x | 93.5% | 85.0% | +1.45% | $1.73B | Benchmark Subject |
| MAZE Maze Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +0.63% | $1.77B | /maze-vs-nvax → |
| REPL Replimune Group Inc. | D | 46/100 | — | — | -35.0% | +8.28% | $1.65B | /repl-vs-nvax → |
| IMCR Immunocore Holdings plc | E | 31/100 | — | 96.0% | -35.0% | -4.11% | $1.61B | /imcr-vs-nvax → |
| COAG Hemab Therapeutics Holdings Inc. | D+ | 57/100 | — | — | — | +4.99% | $1.89B | /coag-vs-nvax → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001000694In its most recent audited fiscal period (FY2025, filed 2025-12-31), Novavax Inc. (NVAX) reported GAAP revenue of $1.12B (+64.7% vs. FY2024 revenue of $682.2M , and +14.2% cumulative change since FY2023) , GAAP net income of $440.3M, operating cash flow of -$244.6M, and free cash flow of -$244.6M (-180.3% YoY). On the balance sheet, NVAX closed FY2025 with $1.18B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.12B | $440.3M | -$244.6M | -$244.6M | $1.18B | — |
| FY2024 (FY) | 2024-12-31 | $682.2M | -$187.5M | -$87.3M | -$87.3M | $1.56B | — |
| FY2023 (FY) | 2023-12-31 | $983.7M | -$545.1M | -$714.0M | -$714.0M | — | — |
3. NVAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NVAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Novavax Inc. (NASDAQ: NVAX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $10.47 (+1.45% 1D, market cap $1.73B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, NVAX ranks #261 in composite RQD confidence.
How does NVAX compare to MAZE and REPL in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NVAX carries a Roarable D+ (56/100 RQD), trailing P/E of 3.9x, gross margin of 93.5%, and ROIC of 85.0%. By comparison, MAZE (Maze Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.77B) and REPL (Replimune Group Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.65B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NVAX?
Per NVAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001000694), Novavax Inc. generated $1.12B in revenue (+64.7% YoY), $440.3M in net income, and -$244.6M in free cash flow against $1.18B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NVAX trading relative to its 50-day, 200-day, and 52-week technical levels?
NVAX last traded at $10.47 (+1.45% on volume of 2,800,169 shares), positioning the stock +0.10% above its 50-day simple moving average ($10.46) and +12.70% above its 200-day simple moving average ($9.29). Across its 52-week range of $6.20 to $13.39, NVAX sits at the 59.4% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.16 to $11.78).
NVAX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NVAX stock moving today?
Why NVAX Stock advanced +1.45% Today — RQD Quant Desk Flash. Stretched risk/reward at 4x P/E (85% return on capital) under elevated 10-year interest-rate pressure.